{"id":53271,"date":"2023-01-25T12:02:14","date_gmt":"2023-01-25T11:02:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/"},"modified":"2023-01-25T12:02:14","modified_gmt":"2023-01-25T11:02:14","slug":"global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/","title":{"rendered":"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4989316\/polycystic-ovarian-syndrome-pipeline-insight?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=d87kql&amp;utm_campaign=1812496+-+Global+Polycystic+Ovarian+Syndrome+Pipeline+Insight+Report+2022%3A+Featuring+Dexa+Medica%2C+AbbVie%2C+Kindex+Pharmaceuticals+and+Spruce+Biosciences+Among+Others&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Polycystic Ovarian Syndrome &#8211; Pipeline Insight, 2022&#8221;<\/a> clinical trials has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230125005386\/en\/1695480\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230125005386\/en\/1695480\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Polycystic ovarian syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n<p>\nThe report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic ovarian syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovarian syndrome treatment guidelines.\n<\/p>\n<p>\nThe assessment part of the report embraces, in depth Polycystic ovarian syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.\n<\/p>\n<p>\nThe companies and academics are working to assess challenges and seek opportunities that could influence in Polycystic ovarian syndrome R&amp;D. The therapies under development are focused on novel approaches to treat\/improve in Polycystic ovarian syndrome.\n<\/p>\n<p>\nThis segment of the Polycystic ovarian syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n<p>\n<strong>Polycystic ovarian syndrome Emerging Drugs<\/strong>\n<\/p>\n<p>\n<strong>DLBS3233: Dexa Medica<\/strong>\n<\/p>\n<p>\nTrofinetide is an investigational drug. It is a novel synthetic analog of the amino-terminal tripeptide of IGF-1 designed to treat the core symptoms of Polycystic ovarian syndrome by potentially reducing neuroinflammation and supporting synaptic function. Trofinetide is thought to stimulate synaptic maturation and overcome the synaptic and neuronal immaturities that are characteristic of Polycystic ovarian syndrome pathophysiology.\n<\/p>\n<p>\nIn the central nervous system, IGF-1 is produced by both of the major types of brain cells &#8211; neurons and glia. IGF-1 in the brain is critical for both normal development and for response to injury and disease. Trofinetide has been shown to inhibit the production of inflammatory cytokines, inhibit the overactivation of microglia and astrocytes, and increase the amount of available IGF-1 that can bind to IGF-1 receptors.\n<\/p>\n<p>\n<strong>Polycystic ovarian syndrome: Therapeutic Assessment<\/strong>\n<\/p>\n<p>\nThis segment of the report provides insights about the different Polycystic ovarian syndrome drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n<p>\n<strong>Major Players in Polycystic ovarian syndrome<\/strong>\n<\/p>\n<p>\nThere are approx. 5+ key companies which are developing the therapies for Polycystic ovarian syndrome. The companies which have their Polycystic ovarian syndrome drug candidates in the most advanced stage, i.e. Phase III include, Dexa Medica.\n<\/p>\n<p>\n<strong>Phases<\/strong>\n<\/p>\n<p>\nThe report covers around 7+ products under different phases of clinical development like\n<\/p>\n<ul>\n<li>\nLate stage products (Phase III)\n<\/li>\n<li>\nMid-stage products (Phase II)\n<\/li>\n<li>\nEarly-stage product (Phase I) along with the details of\n<\/li>\n<li>\nPre-clinical and Discovery stage candidates\n<\/li>\n<li>\nDiscontinued &amp; Inactive candidates\n<\/li>\n<li>\nRoute of Administration\n<\/li>\n<\/ul>\n<p>\n<strong>Polycystic ovarian syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong>\n<\/p>\n<ul>\n<li>\nIntravenous\n<\/li>\n<li>\nMolecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>Products have been categorized under various Molecule types such as<\/strong>\n<\/p>\n<ul>\n<li>\nPeptide\n<\/li>\n<li>\nProtein\n<\/li>\n<li>\nPropylene glycols\n<\/li>\n<li>\nCell Therapy\n<\/li>\n<\/ul>\n<p>\nDrugs have been categorized under various product types like Mono, Combination and Mono\/Combination.\n<\/p>\n<p>\nPolycystic ovarian syndrome: Pipeline Development Activities\n<\/p>\n<p>\nThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic ovarian syndrome therapeutic drugs key players involved in developing key drugs.\n<\/p>\n<p>\n<strong>Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic ovarian syndrome drugs.\n<\/p>\n<p>\n<strong>Polycystic ovarian syndrome Report Insights<\/strong>\n<\/p>\n<ul>\n<li>\nPolycystic ovarian syndrome Pipeline Analysis\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<li>\nImpact of Drugs\n<\/li>\n<\/ul>\n<p>\n<strong>Polycystic ovarian syndrome Report Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Product Profiles\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nPipeline Assessment\n<\/li>\n<li>\nInactive drugs assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Questions<\/strong>\n<\/p>\n<p>\n<strong>Current Treatment Scenario and Emerging Therapies:<\/strong>\n<\/p>\n<ul>\n<li>\nHow many companies are developing Polycystic ovarian syndrome drugs?\n<\/li>\n<li>\nHow many Polycystic ovarian syndrome drugs are developed by each company?\n<\/li>\n<li>\nHow many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic ovarian syndrome?\n<\/li>\n<li>\nWhat are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Polycystic ovarian syndrome therapeutics?\n<\/li>\n<li>\nWhat are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?\n<\/li>\n<li>\nWhat are the clinical studies going on for Polycystic ovarian syndrome and their status?\n<\/li>\n<li>\nWhat are the key designations that have been granted to the emerging drugs?\n<\/li>\n<\/ul>\n<p>\n<strong>Key Players<\/strong>\n<\/p>\n<ul>\n<li>\nDexa Medica Group\n<\/li>\n<li>\nAbbVie\n<\/li>\n<li>\nKindex Pharmaceuticals\n<\/li>\n<li>\nSpruce Biosciences\n<\/li>\n<li>\nBioresearch\n<\/li>\n<li>\nForendo Pharma\n<\/li>\n<li>\nCadila healthcare\n<\/li>\n<\/ul>\n<p>\n<strong>Key Products<\/strong>\n<\/p>\n<ul>\n<li>\nDLBS3233\n<\/li>\n<li>\nElagolix\n<\/li>\n<li>\nKDT 501\n<\/li>\n<li>\nTildacerfont\n<\/li>\n<li>\nHSD17B5 inhibitor\n<\/li>\n<\/ul>\n<p>\nFor more information about this clinical trials report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4989316\/polycystic-ovarian-syndrome-pipeline-insight?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=d87kql&amp;utm_campaign=1812496+-+Global+Polycystic+Ovarian+Syndrome+Pipeline+Insight+Report+2022%3A+Featuring+Dexa+Medica%2C+AbbVie%2C+Kindex+Pharmaceuticals+and+Spruce+Biosciences+Among+Others&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/d9ytaj<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#58;p&#x72;&#101;s&#x73;&#64;r&#x65;&#115;e&#x61;&#114;&#x63;&#x68;&#97;&#x6e;&#x64;&#109;&#x61;&#114;k&#x65;&#116;s&#x2e;&#99;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;&#x65;s&#115;&#x40;r&#101;&#x73;e&#97;&#x72;c&#104;&#x61;&#x6e;&#100;&#x6d;&#x61;r&#107;&#x65;t&#115;&#x2e;c&#111;&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Polycystic Ovarian Syndrome &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Polycystic ovarian syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53271","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Polycystic Ovarian Syndrome &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Polycystic ovarian syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-25T11:02:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230125005386\/en\/1695480\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2023-01-25T11:02:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/\"},\"wordCount\":884,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230125005386\\\/en\\\/1695480\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/\",\"name\":\"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230125005386\\\/en\\\/1695480\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-01-25T11:02:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230125005386\\\/en\\\/1695480\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230125005386\\\/en\\\/1695480\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Polycystic Ovarian Syndrome &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Polycystic ovarian syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-25T11:02:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230125005386\/en\/1695480\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others &#8211; ResearchAndMarkets.com","datePublished":"2023-01-25T11:02:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/"},"wordCount":884,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230125005386\/en\/1695480\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/","name":"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230125005386\/en\/1695480\/21\/logo.jpg","datePublished":"2023-01-25T11:02:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230125005386\/en\/1695480\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230125005386\/en\/1695480\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-polycystic-ovarian-syndrome-pipeline-insight-report-2022-featuring-dexa-medica-abbvie-kindex-pharmaceuticals-and-spruce-biosciences-among-others-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Polycystic Ovarian Syndrome Pipeline Insight Report 2022: Featuring Dexa Medica, AbbVie, Kindex Pharmaceuticals and Spruce Biosciences Among Others &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53271"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53271\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}